Ann: ACTION3 IND Approved in China, page-39

It is not first time in ASX where price being manipulated after a significant announcement. What I can say at this state if we've a commercial deal with with China and US the upfront revenue could be in order of $20M each with conditional revenue in the range of 250M each on the basis of ADVANZ pharma deal. If the commercial agreement happens after the March report and results have statistical significance, double the that amount.

Just sit down and get relaxed. We're surrounded by vultures who want your cheap share as cheap as possible and they will downplay everything, some all of sudden will become Medical Statistician, can interpret double blind reports, talk about futility, take a blind fold on upcoming commercial agreement, will not accept the recent recept of $11.7M revenue (with potential revenue of $232M) from Advanz pharma.

HOLD it tight and keep believing in DXB team, we'll be part of their success journey.